Research ArticleBasic Science Investigations

Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer

Vessela Vassileva, Vineeth Rajkumar, Mario Mazzantini, Mathew Robson, Adam Badar, Surinder Sharma, Erik Årstad, Daniel Hochhauser, Mark F. Lythgoe, Geoffrey M. Boxer and Rosmund Barbara Pedley
Journal of Nuclear Medicine August 2015, 56 (8) 1239-1245; DOI: https://doi.org/10.2967/jnumed.115.157362

This article has a correction. Please see:

Abstract

Despite extensive efforts to improve the clinical management of patients with colorectal cancer, approved treatments for advanced disease offer limited survival benefit. Therefore, the identification of novel treatment strategies is essential. We evaluated the preclinical efficacy of combination radioimmunotherapy, using a humanized 131I-labeled anti-carcinoembryonic antigen antibody (131I-huA5B7), with cetuximab in colorectal cancer (CRC). Methods: Three human CRC cell lines—SW1222, LoVo, and LS174T—were used to generate subcutaneous xenografts, and stably luciferase-transfected SW1222 cells were used to establish a model of hepatic metastases in immunocompromised mice. Imaging and biodistribution studies were conducted to confirm the selective tumor localization of 131I-huA5B7. Efficacy was evaluated on the basis of tumor growth delay and survival, along with markers of DNA damage response, cell cycle, proliferation, and apoptosis. Results: Selective tumor targeting was achieved with 131I-huA5B7 alone or in combination with cetuximab without observable toxicity. Compared with monotherapy, combining cetuximab with radioimmunotherapy significantly and synergistically reduced tumor growth and prolonged survival of mice in 2 of the subcutaneous and in the metastatic tumor model. Evidence of DNA damage, G2/M arrest, significantly decreased proliferation, and increased apoptosis were observed with radioimmunotherapy and the combination therapy. However, a significant decrease in DNA-protein kinase expression with the combination regimen suggests that the addition of cetuximab suppressed DNA repair. Conclusion: Our results demonstrate enhanced therapeutic efficacy with the combination of cetuximab and radioimmunotherapy in CRC, which could potentially translate into successful clinical outcomes. This strategy could improve the treatment of residual disease postoperatively and ultimately prevent or delay recurrence. Furthermore, other carcinoembryonic antigen–expressing malignancies could also benefit from this approach.

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of cancer-related deaths worldwide (1,2). More than 20% of patients are diagnosed with advanced metastatic disease, with a 5-y survival of less than 10%. Despite extensive efforts to improve the clinical management of patients with CRC, approved treatments offer limited survival benefit; therefore, alternative therapeutic strategies need to be explored.

Radiotherapy has an important role in controlling local disease, increasing the possibility of resection and extending survival; however, it cannot achieve systemic reduction of metastatic disease. The use of more-targeted treatments, such as radioimmunotherapy, provides the opportunity to treat localized, metastatic, diffuse, and occult disease. Radioimmunotherapy can selectively target tumor cell– or tumor microenvironment–associated antigens with radiolabeled antibodies, delivering the greatest dose of ionizing radiation (IR) to tumor sites, while minimizing toxicity to normal tissues (3–5). We, and others, have previously shown that radioimmunotherapy against carcinoembryonic antigen (CEA) produced response in patients with advanced CRC; however, although some patients experienced partial remission or disease stabilization, most had disease progression (6–9). Radioimmunotherapy has been successfully used for the treatment of lymphoma, but its use in solid tumors remains to be optimized. Radioresistance, low tumor uptake, and heterogeneous distribution of radiolabeled antibodies are contributing factors to the limitations of radioimmunotherapy. To overcome these challenges, effective combination strategies that could have synergistic or additive effects with minimal toxicity should be investigated.

IR can damage DNA by producing single- and double-strand breaks (10). IR-induced DNA damage activates several signaling cascades that control cell cycle and DNA repair. Double-strand breaks are the most lethal form of damage, and inefficient repair and accumulation of double-strand breaks leads to chromosome aberrations that kill cells through apoptosis or mitotic death. Inhibition of the DNA damage response and repair is a promising strategy for sensitizing cancer cells to the lethal effects induced by IR.

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of tumors, including in 60%–80% of CRCs, and is directly implicated in disease initiation and progression, resistance to therapy, and poor prognosis (11). IR induces the nuclear translocation of EGFR, where it associates with the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), stimulating the repair of double-strand breaks.

The use of EGFR inhibitors, such as cetuximab, hinders DNA repair by blocking the nuclear translocation of EGFR and hence increases the sensitivity of cells to ionizing radiation (12). The ability of cetuximab as a radiosensitizer has been demonstrated in head and neck cancer (13,14) and in vitro in CRC cell lines (15). To our knowledge, there are no reports that have specifically addressed the combination of cetuximab with radioimmunotherapy in CRC. The main objective of this study was to assess the effect of combining cetuximab with radioimmunotherapy, using a humanized 131I-labeled anti-CEA antibody (131I-huA5B7), in preclinical models of CRC.

MATERIALS AND METHODS

Agents and Antibody Labeling

Cetuximab (Erbitux [Merck], 5 mg/mL solution) was purchased from the University College London Hospital Pharmacy. HuA5B7 was provided by UCB Pharma S.A. and labeled with 131I (131I-huA5B7) (Perkin Elmer, U.K.) using the IODO-GEN (Pierce) method as previously described (16,17). Labeling yield and radiochemical purity were assessed by thin-layer chromatography (silica gel Si60, stationary phase; 80% methanol, mobile phase); antigen binding of the radiolabeled antibody was compared with nonlabeled huA5B7 and assessed by enzyme-linked immunosorbent assay.

Cell Lines

Human colorectal adenocarcinoma cell lines SW1222, LoVo, and LS174T were obtained from the European Collection of Cell Cultures. All 3 cell lines are reported to have KRAS mutations (A146V, G13D/A14V, and G12D, respectively) (18,19). Cells were maintained in Dulbecco modified Eagle medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37°C under humidified atmosphere containing 5% CO2.

Tumor Models

Female nude CD-1 and MF-1 mice (age, 6–8 wk; weight, 20–25 g) were purchased from Charles River and Harlan Laboratories, respectively. All animal experiments were performed in accordance with the U.K. Home Office Animals Scientific Procedures Act 1986 and United Kingdom Co-ordinating Committee on Cancer Research Guidelines for the Welfare and Use of Animals in Cancer Research (20) and approved by the University College London Animal Welfare and Ethical Review Body under project license 70-309.

Subcutaneous xenografts were established in CD-1 nude mice using SW1222, LoVo, or LS174T cells. Briefly, 5 × 106 cells were injected into the right flank of mice and allowed to grow to a mean volume of 0.1 cm3. Tumor volumes were caliper-measured and calculated using the formula volume = 4π/3 (1/2 length × 1/2 width × 1/2 height). Mice were sacrificed when tumors reached 1.5 cm3 (endpoint).

Orthotopic models of hepatic metastases were generated in MF-1 nude mice using SW1222 cells transfected with the luciferase gene (SW1222 Luc cells). Briefly, 2 × 106 cells were injected into the spleen, followed by a splenectomy after 10 min (21,22). Hepatic tumor growth was monitored by bioluminescence imaging using the IVIS system (Xenogen/Caliper Life Sciences) as previously described (23). The Living Image Software (Xenogen/Caliper Life Sciences) was used to obtain and analyze images. Regions of interest were created and the counts per second measured (tumor regions in each group had an average of 2.1 × 106 total counts/s at the start of the studies, ∼14 d after tumor cell inoculation).

Localization and Biodistribution of 131I-huA5B7

Localization and biodistribution of 131I-huA5B7 was assessed with and without cetuximab, at 2, 6, and 10 d after administration in the subcutaneous tumor models and at 2 d in the metastatic tumor model. Briefly, mice (n = 4, per group) were injected intravenously with 1 MBq (131I-huA5B7, 0.25 μg, in total volume of 100 μL of sterile saline) with or without cetuximab (10 mg/kg) administered intraperitoneally 4 h before radioimmunotherapy and imaged using SPECT/CT (Silver Upgrade NanoSPECT/CT; Mediso) at the selected time points. Mice were then euthanized, and tissues (blood, liver, kidney, lung, spleen, colon, muscle, tumor) were collected, weighed, and γ-counted (WIZARD; PerkinElmer, U.K.). The uptake of 131I-huA5B7 was calculated as percentage injected activity per gram of tissue.

Efficacy Studies

Efficacy studies were performed in the subcutaneous SW1222, LoVo, and LS174T cell lines and in the metastatic tumor model. Mice with similar tumor burden were allocated to the following groups, n = 8 per group: untreated, cetuximab, 131I-huA5B7, and cetuximab combined with 131I-huA5B7. Cetuximab (10 mg/kg) was administered intraperitoneally twice weekly, radioimmunotherapy consisted of a single intravenous injection of 131I-huA5B7 (1 MBq), and the combined treatment involved administration of cetuximab 4 h before 131I-huA5B7 and twice weekly as maintenance therapy. Tumor volumes were measured, and mice were weighed every 2–3 d throughout the duration of the study until endpoint. In the metastatic model, tumor burden was assessed by bioluminescence imaging as described above; mice were imaged every 2–3 d to monitor tumor growth over time. Disease progression was also evaluated qualitatively by observation of behavior, weight loss, muscle wasting, and abdominal distension, as previously described (24,25). Animals were sacrificed when a signal of greater 2 × 107 total counts/s was measured, which correlated with the qualitative measurements of disease progression.

Efficacy with various activities (0.5, 1, 1.5, and 2 MBq) of 131I-huA5B7 (0.25 μg, in total volume of 100 μL of sterile saline) alone or in combination with cetuximab was assessed in the subcutaneous SW1222 model.

Tumor growth curves based on changes in tumor volume or bioluminescence over time and survival were used to evaluate treatment efficacy.

Immunohistochemistry

CEA expression was confirmed in all tumor models as previously described (16). Markers of DNA damage response (γH2AX and DNA-PK), cell cycle (phospho-histone H3, cyclin B1), proliferation (Ki-67), and apoptosis (caspase-3) were examined in tumor sections from each group at 2, 6, and 10 d after treatment initiation. After antigen retrieval, sections were incubated with primary antibodies either for 1 h at room temperature for cyclin B1 (Abcam, 1:200), phospho-histone H3 (Millipore, 1:200), and Ki-67 (Dako, 1:300) or overnight at 4°C for γ-H2AX (Millipore, 1:500), DNA-PK (Abcam, 1:500), and cleaved caspase-3 (Cell Signaling, 1:500) and visualized using biotin-conjugated secondary antibodies (Vectastain ABC Kit; Vector Labs) and 3, 3′-diaminobenzidine (DAB; Dako). Sections were then counterstained with hematoxylin, dehydrated, and mounted with DPX (Sigma Aldrich).

Image Analyses and Quantification

Image acquisition and analysis were performed using the TissueGnostics software (microscope, AxioImager Z.2; Zeiss). Briefly, regions of interest were used to select viable tumor tissue and excluded necrotic areas. Cell-based analysis was performed with automated cell segmentation based on color: hematoxylin in the blue and DAB in the red channel. To avoid artifacts, a threshold for minimum cell area and variance of hematoxylin staining was set. Positive cells were selected on the basis of mean and maximum intensity of DAB. Data were generated by calculating the percentage of the DAB-reactive cells in relation to the total number of cells in the regions of interest.

Combination Analyses

The Bliss independence model was used to calculate whether the combination therapy was synergistic. Briefly, this method compares the observed response of the combination with the predicted response, which was obtained using the assumption that there is no effect from drug–drug interactions (26). Typically, the combination effect is declared synergistic if the observed response is greater than predicted response.

Statistical Analyses

Data were plotted and analyzed using Prism software (version 6.0; GraphPad Software). Differences in tumor growth and immunohistochemistry markers between the groups were assessed by 2-way ANOVA and multiple t tests. Kaplan–Meier survival plots were analyzed using the log-rank test. Results were considered statistically significant at a P value of 0.05 or less.

RESULTS

Localization and Biodistribution of 131I-huA5B7 and Efficacy of Combination Therapy in Subcutaneous Xenografts

Whole-body SPECT/CT of tumor-bearing mice demonstrated highly selective tumor localization of 131I-huA5B7 at 2, 6, and 10 d after administration (Fig. 1A). Prolonged and high tumor retention of 131I-huA5B7 was observed, compared with normal tissues (Figs. 1B–1D). The addition of cetuximab did not significantly alter the biodistribution of 131I-huA5B7.

FIGURE 1.
FIGURE 1.

Localization and biodistribution of 131I-huA5B7 in subcutaneous tumor xenografts. (A) Representative whole-body SPECT/CT images from SW1222 tumor model. Color bar represents counts per second with maximum and minimum threshold levels. Biodistribution of 131I-huA5B7 alone or in combination with cetuximab in tissues at 2, 6, and 10 d after administration in SW1222 tumor model (B), LoVo tumor model (C), and LS174T tumor model (D) is shown. Data presented as mean percentage injected activity per gram of tissue ± SE.

Overall, the combination therapy significantly delayed tumor growth and prolonged survival, compared with each monotherapy, in the SW1222 and LoVo tumor model but not in the LS174T xenograft (Fig. 2).

FIGURE 2.
FIGURE 2.

Efficacy of cetuximab, 131I-huA5B7, and combination therapy evaluated as tumor growth and survival in subcutaneous tumor models SW1222 (A), LoVo (B), and LS174T (C). Tumor growth presented as mean fraction tumor volume change over time ± SE, and survival data presented as Kaplan–Meier plots. Combination therapy significantly delayed tumor growth and prolonged survival, compared with each monotherapy in SW1222 and LoVo tumor model (P < 0.05, 2-way ANOVA, multiple t tests, and log-rank test).

Compared with untreated mice, radioimmunotherapy significantly reduced tumor growth and prolonged survival in all 3 tumor models, whereas cetuximab had an effect in the SW1222 and LoVo xenografts. The median survival of untreated, cetuximab, 131I-huA5B7, and combination-treated mice for all 3 tumor models is displayed in Table 1. No observable toxicities were detected in any of the groups from all studies.

View this table:
TABLE 1

Median Survival of Mice Treated with 1 MBq of Radioimmunotherapy

Localization and Biodistribution of 131I-huA5B7 and Efficacy of Combination Therapy in Model of Hepatic Metastases

Similar to our findings in the subcutaneous tumor models, SPECT/CT imaging of tumor-bearing mice and phosphor images of liver sections with tumor deposits showed selective tumor localization of 131I-huA5B7, 2 d after administration (Fig. 3A). The combination therapy significantly improved response, compared with each monotherapy, based on tumor growth delay as evaluated by bioluminescence imaging and survival analyses (Figs. 3B and 3C). Compared with untreated mice, each monotherapy also significantly delayed tumor growth and prolonged survival (Figs. 3B and 3C). The median survival of untreated, cetuximab, 131I-huA5B7, and combination-treated mice was 12.5, 14, 18, and 27 d, respectively.

FIGURE 3.
FIGURE 3.

Efficacy of combination therapy in model of hepatic metastases. In vivo and ex vivo localization of 131I-huA5B7 2 d after administration (A), representative bioluminescence images of 3 mice from each group (B), tumor growth represented as fractional change in bioluminescence over time (C), mean ± SE and survival of mice, Kaplan–Meier plots. Combination therapy significantly delayed tumor growth and prolonged survival, compared with each monotherapy (P < 0.05, 2-way ANOVA, multiple t tests, and log-rank test). H&E = hematoxylin and eosin.

Effect of Increasing Activity of Radioimmunotherapy Alone or in Combination with Cetuximab in SW1222 Subcutaneous Model

The studies with a range of activities of 131I-huA5B7 (0.5, 1, 1.5, and 2 MBq) demonstrated that the addition of cetuximab to radioimmunotherapy significantly enhanced response, compared with each corresponding treatment with radioimmunotherapy alone (Fig. 4).

FIGURE 4.
FIGURE 4.

Efficacy in response to a range of activities of 131I-huA5B7 alone or in combination with cetuximab. Tumor growth represented as mean fraction tumor volume change over time ± SE, and survival data presented as Kaplan–Meier plots. Addition of cetuximab to radioimmunotherapy significantly enhanced response, compared with each corresponding treatment with radioimmunotherapy alone (P < 0.05, 2-way ANOVA, multiple t tests, and log-rank test).

No significant difference in response was observed between the radioimmunotherapy-alone groups and also between the combination-therapy groups, except with 0.5 MBq.

The response to the combination therapy with 0.5 MBq was not significantly different from the response with 2 MBq of radioimmunotherapy alone, demonstrating that significantly lower activity of radioimmunotherapy can be used in combination with cetuximab to achieve similar effects. Combination therapy with 1 or 1.5 MBq significantly delayed tumor growth and prolonged survival, compared with 2 MBq of radioimmunotherapy alone.

The median survival of untreated and cetuximab-treated mice was 20 and 35 d. For mice treated with 0.5, 1.0, 1.5, and 2.0 MBq, median survival was 22.5, 35, 36, and 33 d, respectively, and 29, 57, 57, and 52 d for mice treated with the corresponding activity when combined with cetuximab.

Effect of Therapy on DNA Damage Response, Cell Cycle, Proliferation, and Apoptosis

Immunohistochemistry revealed that all xenografts expressed CEA. SW1222 and LS174T tumors had a relatively higher CEA expression than LoVo tumors (Supplemental Fig. 1; supplemental materials are available at http://jnm.snmjournals.org).

Markers of DNA damage response, cell cycle, proliferation, and apoptosis were examined in tumor sections from the SW1222 tumor model at 2, 6, and 10 d after treatment initiation. Evidence of DNA damage and repair were observed with radioimmunotherapy when administered alone or in combination with cetuximab (Fig. 5A). However, there was a significant decrease in DNA-PK at days 6 and 10 with the combination therapy, compared with radioimmunotherapy alone, suggesting that cetuximab suppressed DNA repair. Significantly decreased phospho-histone H3 and mainly cytoplasmic cyclin B1 expression suggested a G2/M arrest with radioimmunotherapy and the combination therapy, which was also accompanied by a significant decrease in proliferation and increase in apoptosis (Figs. 5B and 5C). A significant decrease in the percentage of cells undergoing mitosis and proliferation was observed with the combination therapy, compared with radioimmunotherapy at day 10.

FIGURE 5.
FIGURE 5.

Effect of therapy in subcutaneous SW1222 xenografts on DNA damage response (γH2AX, DNA-PK) (A); cell cycle, proliferation, and apoptosis (phospho-histone H3, Ki-67, and cleaved caspase-3) (B); and G2/M phase of cell cycle (C) (representative tumor sections from each group showing cyclin B1 distribution). Quantitative immunohistochemistry data presented as mean percentage of positive cells ± SE. DNA damage and repair were observed with radioimmunotherapy when administered alone or in combination with cetuximab. Significant decrease in DNA-PK was detected with combination therapy at days 6 and 10, compared with radioimmunotherapy (P < 0.05, Student t test). Significantly decreased phospho-histone H3 and mainly cytoplasmic cyclin B1 expression were observed with radioimmunotherapy and combination therapy, which was also accompanied by significant decrease in proliferation and increase in apoptosis (P < 0.05, Student t test). *Indicates significantly different from untreated. **Indicates significantly different from untreated and cetuximab. ***Indicates significantly different from untreated, cetuximab, and 131I-huA5B7 (P < 0.05, ANOVA, multiple t tests).

Synergy

The observed combined response with cetuximab and 131I-huA5B7 was significantly greater than the predicted response for the SW1222 (subcutaneous and metastatic) and the LoVo tumor models, indicating that the combination treatment was more efficacious than expected, which is representative of synergy (Supplemental Fig. 2). Synergy occurred from day 17 and 14 in the SW1222 subcutaneous and metastatic tumor model, respectively, and from day 45 in the LoVo tumor model. Moreover, synergy was also observed with the range of activities of radioimmunotherapy in combination with cetuximab, even with the lowest activity of 0.5 MBq, where it occurred from day 25.

DISCUSSION

We have demonstrated that combining cetuximab with 131I-huA5B7 significantly and synergistically improved therapeutic efficacy in subcutaneous and metastatic preclinical models of CRC. This enhanced therapeutic response was achieved without observable toxicity and with significantly lower than clinically used activities of radioimmunotherapy. To our knowledge, our study is the first to examine this combination strategy in CRC. In addition to its use as a therapeutic modality, radioimmunotherapy can also be simultaneously used as an imaging technique to detect the localization of the radiolabeled antibody within tumors and normal tissues.

After the confirmation of the selective localization of 131I-huA5B7 to tumor sites, the effect of the combination therapy was examined in 3 distinct subcutaneous models of CRC (SW1222, LoVo, and LS174T). Combining cetuximab with radioimmunotherapy resulted in significantly delayed tumor growth and prolonged survival, compared with each monotherapy, in both the SW1222 and the LoVo xenografts but not in the LS174 tumor model, which was responsive only to radioimmunotherapy. Clearly, the genetic variability of tumors can influence response to treatment. Although all of the 3 cell lines possess KRAS mutations, the LS174T cells harbor an additional mutation in PI3CA, which likely contributes to augmented signaling in the RAS-RAF-MEK-MAPK pathway and increased resistance to cetuximab. Although it is widely accepted that mutations in KRAS predict response to cetuximab in CRC, our data suggest that additional mutations in other genes, which contribute to augmented signaling in the RAS-RAF-MEK-MAPK or PI3K-AKT-mTOR pathways, likely lead to cetuximab resistance. Therefore, cetuximab should not be disregarded in KRAS-mutant tumors, especially when combined with radioimmunotherapy, unless they harbor additional mutations in downstream signaling pathways. Indeed, patients with CRC bearing a G12D or a G13D mutation have been described to have a more favorable outcome than other KRAS mutations, contrary to previous reports (27,28).

The enhanced tumor responsiveness to the combination therapy in the SW1222 and LoVo tumor models could be as a result of selectively localized and prolonged radiation exposure and damage from radioimmunotherapy plus reduced DNA repair due to inhibition of EGFR function by cetuximab. Overall, we observed evidence of simultaneous DNA damage and repair with radioimmunotherapy alone or in combination with cetuximab. However, DNA-PK expression was lower in the combination-therapy group than in the radioimmunotherapy group, suggesting that the addition of cetuximab affected DNA repair. Even a small decrease in DNA-PK activity could result in a significantly reduced capacity of DNA repair (12). These data were also accompanied by evidence of a G2/M arrest, significantly decreased proliferation, and increased apoptosis.

Overall, our findings suggest that DNA damage occurs and accumulates with radioimmunotherapy leading to a G2/M arrest, some DNA repair, decreased proliferation, and increased apoptosis; however, the addition of cetuximab impedes DNA repair and enhances efficacy, potentially via mechanisms other than apoptosis, such as mitotic catastrophe and senescence, supported by the decreased level of mitotic and proliferating cells with the combination therapy at the latest time point. The effectiveness of the combination therapy was further confirmed in a more clinically relevant model of metastasis. Similarly to the subcutaneous xenografts, highly selective tumor localization of 131I-huA5B7 was observed, along with significantly enhanced tumor growth delay and survival, which was significantly enhanced by the addition of cetuximab.

We then investigated whether combining cetuximab with various activities of radioimmunotherapy could further improve therapeutic response in the SW1222 tumor model. Similar therapeutic effect was observed with all activities of radioimmunotherapy alone or when combined with cetuximab, except with 0.5 MBq. Each combination was significantly more effective than monotherapy with radioimmunotherapy or cetuximab.

Combination therapy with 1 or 1.5 MBq significantly delayed tumor growth and prolonged survival, compared with 2 MBq of radioimmunotherapy alone, suggesting that cetuximab is radiosensitizing tumor cells. Similarly, another study also demonstrated increased efficacy with combination therapy in preclinical models of head and neck cancer (29). However, the activities of radioimmunotherapy used in this study were in excess of what is normally administered to patients (6,7,30). To our knowledge, our study is the first to demonstrate that activities as low as 1 MBq of radioimmunotherapy can be therapeutically effective, particularly when combined with radiosensitizing agents, such as cetuximab, which would greatly facilitate the use of repeated radioimmunotherapy administration in patients. Extrapolating 1 MBq to the human equivalent activity corresponds to approximately 154 MBq/m2 (31), which is significantly lower than clinically used activities. Data from an early phase I trial of single-agent 131I-murine A5B7 in patients with advanced CRC defined bone marrow suppression as the dose-limiting toxicity at 2,400 MBq/m2, which was further reduced to 1,600 MBq/m2 in another trial, as a cohort of patients experienced grade 4 neutropenia (6,7,30). Our findings with the humanized version of A5B7 strongly suggest that combining cetuximab with lower activity of radioimmunotherapy could translate into significantly better clinical outcomes with minimal toxicity.

Although we did not have a nonspecific radiolabeled antibody (131I-IgG1/MOPC) control in our studies, we have previously shown no therapeutic effect with a dose of 4 MBq of 131I-IgG1/MOPC in SW1222 tumor metastases (16), suggesting that cross-fire irradiation from circulating antibody does not significantly affect tumor growth. Moreover, our current studies show that 10 d after administration, the tumor-to-blood ratio of huA5B7 is approximately 8:1 in SW1222 tumors with minimal blood levels, which supports the hypothesis that the observed therapeutic effects were due to tumor-bound antibody rather than circulating antibody.

CONCLUSION

We demonstrated that cetuximab synergizes with radioimmunotherapy and radiosensitizes tumor cells to significantly enhance therapeutic response in preclinical models of CRC. This strategy might represent the ideal scenario for the treatment of residual disease postoperatively and ultimately for prevention and delay of recurrence. Furthermore, KRAS-mutant tumors and other CEA-expressing malignancies could also benefit from this approach.

DISCLOSURE

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. This work was supported by MRC DPFS/DCS grant G1001497. Radiolabelling work was performed at UCLH/UCL, partially funded by the Department of Health NIHR Biomedical Research Centers funding scheme. Imaging work was conducted in collaboration with CRUK and EPSRC Comprehensive Cancer Imaging Centre at KCL and UCL, jointly funded by Cancer Research U.K. and the Engineering and Physical Sciences Research Council (EPSRC), grant C1519/A10331 and C1519/A16463. No other potential conflict of interest relevant to this article was reported.

Acknowledgments

We acknowledge Dr. Jane Kinghorn for her support. We are grateful to UCB Pharma S.A, Slough, U.K., for providing the huA5B7 antibody. We also acknowledge Mohammed Rashid and Chiea K. Cheng for their technical support.

Footnotes

  • Published online Jun. 4, 2015.

REFERENCES

  1. 1.↵
    1. Curtin JC
    . Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153–1164.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Siegel R,
    2. Naishadham D,
    3. Jemal A
    . Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Navarro-Teulon I,
    2. Lozza C,
    3. Pelegrin A,
    4. Vives E,
    5. Pouget JP
    . General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013;5:467–487.
    OpenUrlCrossRefPubMed
  4. 4.
    1. Dearling JL,
    2. Pedley RB
    . Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol). 2007;19:457–469.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Pouget J-P,
    2. Navarro-Teulon I,
    3. Bardies M,
    4. et al
    . Clinical radioimmunotherapy: the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720–734.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Lane DM,
    2. Eagle KF,
    3. Begent RH,
    4. et al
    . Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994;70:521–525.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Meyer T,
    2. Gaya AM,
    3. Dancey G,
    4. et al
    . A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009;15:4484–4492.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Juweid ME,
    2. Sharkey RM,
    3. Behr T,
    4. et al
    . Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med. 1996;37:1504–1510.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Hajjar G,
    2. Sharkey RM,
    3. Burton J,
    4. et al
    . Phase I radioimmunotherapy trial with iodine-131–labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31–42.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Santivasi WL,
    2. Xia F
    . Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 2014;21:8.
    OpenUrl
  11. 11.↵
    1. Cunningham D,
    2. Humblet Y,
    3. Siena S,
    4. et al
    . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Liccardi G,
    2. Hartley JA,
    3. Hochhauser D
    . Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage. Clin Cancer Res. 2014;20:3496–3506.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Bonner JA,
    2. Harari PM,
    3. Giralt J,
    4. et al
    . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Bonner JA,
    2. Harari PM,
    3. Giralt J,
    4. et al
    . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–28.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Shin HK,
    2. Kim MS,
    3. Lee JK,
    4. et al
    . Combination effect of cetuximab with radiation in colorectal cancer cells. Tumori. 2010;96:713–720.
    OpenUrlPubMed
  16. 16.↵
    1. El Emir E,
    2. Qureshi U,
    3. Dearling JL,
    4. et al
    . Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007;67:11896–11905.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Rajkumar VS,
    2. Boxer G,
    3. Robson M,
    4. Muddle J,
    5. Papastavrou Y,
    6. Pedley RB
    . A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumour Biol. 2012;33:2019–2029.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Therkildsen C,
    2. Bergmann TK,
    3. Henrichsen-Schnack T,
    4. Ladelund S,
    5. Nilbert M
    . The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53:852–864.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Tol J,
    2. Dijkstra JR,
    3. Klomp M,
    4. et al
    . Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer. 2010;46:1997–2009.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Workman P,
    2. Aboagye EO,
    3. Balkwill F,
    4. et al
    . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–1577.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Rajendran S,
    2. Salwa S,
    3. Gao X,
    4. et al
    . Murine bioluminescent hepatic tumour model. J Vis Exp. 2010;1977.
  22. 22.↵
    1. Dearling JL,
    2. Flynn AA,
    3. Qureshi U,
    4. et al
    . Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. Nucl Med Biol. 2009;36:883–894.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Vassileva V,
    2. Moriyama EH,
    3. De Souza R,
    4. et al
    . Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br J Cancer. 2008;99:2037–2043.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Vassileva V,
    2. Allen CJ,
    3. Piquette-Miller M
    . Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 2008;7:630–637.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Ullman-Culleré MH,
    2. Foltz CJ
    . Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49:319–323.
    OpenUrlPubMed
  26. 26.↵
    1. Zhao W,
    2. Sachsenmeier K,
    3. Zhang L,
    4. Sult E,
    5. Hollingsworth RE,
    6. Yang H
    . A new bliss independence model to analyze drug combination data. J Biomol Screen. 2014;19:817–821.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. De Roock W,
    2. Jonker DJ,
    3. Di Nicolantonio F,
    4. et al
    . Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–1820.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Modest DP,
    2. Brodowicz T,
    3. Stintzing S,
    4. et al
    . Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology. 2012;83:241–247.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Tijink BM,
    2. Neri D,
    3. Leemans CR,
    4. et al
    . Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127–1135.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Casey JL,
    2. Napier MP,
    3. King DJ,
    4. et al
    . Tumour targeting of humanised cross-linked divalent-fab[prime] antibody fragments: a clinical phase I/II study. Br J Cancer. 2002;86:1401–1410.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Freireich EJ,
    2. Gehan EA,
    3. Rall DP,
    4. Schmidt LH,
    5. Skipper HE
    . Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–244.
    OpenUrlPubMed
  • Received for publication March 10, 2015.
  • Accepted for publication May 19, 2015.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords